Multiple and Concomitant Molecular Findings in a Heavily Treated Patient With EGFR-positive Lung Cancer

Clin Lung Cancer. 2021 Mar;22(2):e137-e138. doi: 10.1016/j.cllc.2020.09.001. Epub 2020 Sep 18.

Authors

Fabrizio Citarella¹, Marco Russano², Alessandro Galletti², Bruno Vincenzi², Giuseppe Tonini², Daniele Santini²

Affiliations

¹ Department of Medical Oncology, Università Campus Bio-Medico di Roma, Rome, Italy. Electronic address: f.citarella@unicampus.it.
² Department of Medical Oncology, Università Campus Bio-Medico di Roma, Rome, Italy.

PMID: 33028500
DOI: 10.1016/j.cllc.2020.09.001

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Carcinoma, Non-Small-Cell Lung / genetics
Carcinoma, Non-Small-Cell Lung / pathology
Carcinoma, Non-Small-Cell Lung / therapy
Combined Modality Therapy
Disease Progression
Drug Resistance, Neoplasm / drug effects
Drug Resistance, Neoplasm / genetics
ErbB Receptors / genetics
Fatal Outcome
Humans
Lung Neoplasms / genetics*
Lung Neoplasms / pathology
Lung Neoplasms / therapy*
Male
Middle Aged
Mutation

Substances

EGFR protein, human
ErbB Receptors